Ultime notizie per Mondee Hldgs (NASDAQ:MOND) Azioni

Mondee Hldgs

Mondee Holdings Inc is a travel technology company & marketplace with a portfolio of leisure & corporate travel sectors. The company provides AI platforms, technologies, operating systems, & services that enable travel transactions to serve travelers directly or through travel affiliates. The company has two segments Travel Marketplace & SAAS Platform. The Travel Marketplace segment consists of selling airline tickets through the proprietary platform. The SAAS Platform segment offers corporate travel cost savings solutions through its technology platform. The majority is from the Travel Marketplace segment. Geographically, the key revenue is from the United States.

Mondee Holdings, Inc. - Class A Common Stock

Mondee Holdings Inc

Mondi PLC ADR

Mondi PLC

MONDELEZ INTERNATIONAL CL A ORD

Monday.Com Ltd

Monde Nissin Corp

Mondelez International, Inc. - Class A Common Stock

Mondelez International Inc

MONDIAL VNTRS INC by Mondial Ventures, Inc.

Mondial Ventures Inc

News

Financing

SAVE

Spirit Airlines Reports That On October 11, 2024 The Co Entered Into A Letter Agreement Which Modifies Its Existing Card Processing Agreement To Extend The 2025 Notes Extension Deadline From October 21, 2024 To December 23, 2024 And The Early Maturity Date From December 31, 2024 To March 3, 2025

<p>Village Farms International, Inc. ("Village Farms" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that it is not in compliance with the minimum bid price requirement (NASDAQ Listing Rule) as the bid price for the Company's common shares closed below US $1.00 (the "Minimum Bid Requirement") from September 6, 2024 to October 17, 2024 (the "Notification").</p>
<p>The Notification has no immediate effect on the listing of the Company's common shares on the Nasdaq Capital Market. Under NASDAQ Listing Rule 5810(c)(3)(A), the Company has until April 16, 2025, a period of 180 calendar days from the date of Notification (the "Compliance Period") to regain compliance with the Minimum Bid Requirement. During the Compliance Period, Village Farms common shares will continue to trade on the Nasdaq Capital Market. If at any time before April 16, 2025, the bid price of Village Farms' common shares closes at or above US $1.00 per share for a minimum of 10 consecutive business days, it is expected that Nasdaq would notify the Company that it has regained compliance with the Minimum Bid Requirement.</p>
<p>In the event the Company does not regain compliance with the Minimum Bid Requirement by April 16, 2025, the Company may be eligible for an additional period of 180 calendar days to regain compliance or may be subject to delisting of its common shares from the Nasdaq Capital Market, at which time the Company may appeal the delisting determination to a Nasdaq Hearings Panel.</p>


Village Farms International Received Notice From The Nasdaq That Is Not In Compliance With The Minimum Bid Price Requirement

<p><a href="https://www.globenewswire.com/Tracker?data=H2daQcf_I2GN6OmeR1xFdnTathsgecFtJTGfHE70PDJgU0nJIU-24KVPsKcirEazVMyl3-lQ46pm-zRu7H-YqA==">Celularity&nbsp;Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) (the "Company"), a regenerative medicine company developing and commercializing placental-derived technologies, today announced that it has received a formal notice from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") on October 16, 2024, indicating that the Company is subject to delisting due to its inability to timely file its Forms 10-Q for the the periods ended March 31, 2024, and June 30, 2024 (the "Forms 10-Q") within the prescribed 180-day compliance period. Nasdaq's notice has no immediate effect on the listing of the Company's common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols "CELU" and "CELUW", respectively.</p>
<p>The Company will appeal the determination with the Nasdaq Hearings Panel prior to October 24, 2024, and request a hearing to present its plan to regain compliance and, if necessary, request a stay of suspension pending the hearing. However, there can be no assurance that Nasdaq will accept the plan, that the Company will regain compliance within any additional compliance period, or that the Company will maintain compliance with the other Nasdaq listing requirements.</p>
<p>The Company remains committed to regaining full compliance with Nasdaq's listing requirements. The Company has filed its annual report on Form 10-K for fiscal year 2023 within the compliance period and its quarterly report on Form 10-Q for the first quarter 2024 on October 16, 2024. Additionally, the Company intends to file its Form 10-Q for the second quarter 2024 within the coming weeks.</p>


CELU

Celularity Receives Notice From Nasdaq; Confirms Intention To File An Appeal

<ul>
<li><i>The company delivered 57 aircraft in 3Q24 versus 43 a year ago</i></li>
<li><i>2 C-390 Millennium aircraft delivered during the quarter and 6-12 A-29 Super Tucanos orders</i></li>
<li><i>First E2 aircraft delivered to LOT Polish Airlines</i></li>
<li><i>US$ 22.7 billion company wide backlog, up more than 25% annually and at a 9-year high level</i></li>
<li><i>Defense &amp; Security backlog soared almost 70%</i></li>
</ul>
<p>SÃO PAULO, Oct. 18, 2024 /PRNewswire/ --&nbsp;Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>, B3: EMBR3)))), a global leader in the aerospace industry, delivered a total of 57 jets in 3Q24 – an increase of 33% compared to the same period last year (yoy) and 24% over to the previous quarter (qoq). Commercial aviation delivered 16 jets and Executive aviation delivered another 41 jets. Meanwhile, Defense &amp; Security delivered 2 C-390 Millennium aircraft during the quarter – the first aircraft to Hungary and the seventh to Brazil.</p>


Embraer-Empresa Brasileira De Aeronautica

Embraer Delivered 57 Aircraft In Q3 Versus 43 YoY And Reached A New $22.7B Backlog Record, Up More Than 25% Annually And At A 9-Year High Level

<p>Oak Valley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVLY#NASDAQ">OVLY</a>) reported quarterly earnings of $0.89 per share. This is unchanged from the same period last year.</p>


Earnings

OVLY

Oak Valley Q3 EPS $0.89, Same YoY

<p>The<strong> Kentucky General Assembly's Administrative Regulation Review Subcommittee</strong> has officially approved a set of regulations for medical cannabis businesses ahead of the program's January 1, 2025 launch. </p>
<p>These <a href="https://apps.legislature.ky.gov/law/kar/titles/915/">regulations</a> outline application fees, annual licensing costs, and safety compliance standards for businesses aiming to participate in Kentucky's budding medical cannabis market, <a href="https://www.kentuckytoday.com/news/medical-cannabis-regulations-approved/article_b457ecba-8c01-11ef-a5e4-9f32b53d2a41.html">reported</a> Kentucky Today.</p>
<p>Cultivators fall under <strong>four tiers</strong>, with non-refundable application <strong>fees ranging from $3,000 to $30,000</strong>, based on the <a href="https://www.benzinga.com/general/biotech/23/10/35504268/scaling-profits-with-multi-tier-cannabis-cultivation-growglides-lego-like-solution">scale of cultivation</a>. For processors and dispensaries, the fee is set at $5,000, while safety compliance facilities will pay $3,000. Once approved, annual fees range from $12,000 to $100,000 depending on the tier.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41405555/floridas-cannabis-amendment-record-spending-unlikely-alliances-and-criticism-from-the-catholic-c">Florida&#8217;s Cannabis Amendment: Record Spending, Unlikely Alliances, And Criticism From The Catholic Church</a></strong></p>
<p>Kentucky's Office of Medical Cannabis executive director,<strong> Sam Flynn</strong> said there&#8217;s huge interest in the program, with nearly 5,000 applicants submitting their proposals.</p>
<p>"The total number of applications was 4,998," Flynn stated, highlighting that<em> 4,075 were dispensaries</em> and 923 were cultivators, processors, or compliance facilities. </p>
<p>The initial wave of applications generated an impressive <strong>$27.7 million in non-refundable fees</strong>.</p>
<p>However, Flynn noted that these fees represent a one-time revenue stream. To maintain program sustainability, patient fees &#8211; set at $25 for both initial applications and annual renewals &#8211; will help support ongoing costs. The potential need for additional general fund appropriations may arise in the future to cover shortfalls.</p>
<p>Kentucky recently awarded its first <a href="https://www.benzinga.com/markets/cannabis/24/09/41059061/kentucky-moves-closer-to-medical-cannabis-rollout-with-first-license-awarded-to-testing-lab">medical cannabis </a>license to a testing lab.</p>
<p>Meanwhile, Kentucky is gearing up for its next step, with plans to distribute licenses to cultivators and processors through a <a href="https://www.benzinga.com/markets/cannabis/24/09/41059061/kentucky-moves-closer-to-medical-cannabis-rollout-with-first-license-awarded-to-testing-lab">lottery system</a> set for October 28.</p>
<ul>
<li><strong>Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/10/41368890/florida-sheriff-backs-cannabis-legalization-amendment-im-a-conservative-with-strong-faith-and-fa"> Florida Sheriff Backs Cannabis Legalization Amendment: &#8216;I&#8217;m A Conservative With Strong Faith And Family Values&#8217;</a></strong></li>
</ul>
<p><em>Cover: AI generated image</em></p>


Cannabis

Government

Regulations

Markets

Huge Interest In Medical Cannabis Licenses In Kentucky, Nearly 5,000 Applications, Fees Announced

<p>Many investors still hold high regard for the <a href="https://www.marketbeat.com/stocks/sectors/computer-and-technology/">technology sector</a> in the United States today, which makes sense as the services PMI index is carrying most&mdash;if not all&mdash;of the economic growth left in the country, compared to the 23-month contraction in the <a href="https://www.marketbeat.com/stocks/sectors/manufacturing/">manufacturing sector</a>, as seen in that PMI index. However, not all technology sectors are equal.</p>
<p>The <a href="https://www.marketbeat.com/compare-stocks/semiconductor-stocks/">semiconductor and chipmaking</a> niche of the sector receives special attention, which has been present all of 2024 and extrapolated since the shortages seen since the COVID-19 pandemic. In recent quarters, all the pressure seems to have been placed on shares of <strong>Taiwan Semiconductor Manufacturing Co. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>), the global leader in chip sales with major customers all over the sector.</p>
<p>However, investors might have been concerned after seeing <strong>NVIDIA Co. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvidia#NASDAQ">NVIDIA</a>) sell-off after its last quarter, which announced a state of &quot;<a href="https://www.hindustantimes.com/business/nvidias-ceo-jensen-huang-says-new-chip-will-have-lots-and-lots-of-supply-101725536426366.html">lots and lots of supply</a>,&quot; according to its CEO, which would ultimately hurt margins and earnings per share (EPS). More recently, <strong>ASML Holding </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asml#NASDAQ">ASML</a>) stock sold off by over 17% in a single day after <a href="https://www.marketbeat.com/stock-ideas/asmls-earnings-miss-opens-door-for-savvy-investors/">missing booking guidance</a>.</p>
<h3><strong>Taiwan Semiconductor Stock Soars 12%: Strong Earnings and Growing Demand Fuel Rally</strong></h3>
<p>To ease some of the ASML and NVIDIA concerns, Taiwan Semiconductor stock rallied by over 12% in a single day following the blowout earnings results posted. This may have caused a surprise figure to outperform some of its peers during the quarter.</p>
<p>Investors <a href="https://www.marketbeat.com/stock-ideas/taiwan-semiconductor-stock-buy-now-or-wait-for-earnings/">would have been ready</a> for this rally by looking at a few metrics beforehand. Some of these metrics include the monthly revenue growth rate and the fact that markets were willing to pay a premium valuation only to get exposure to the company&#39;s future earnings, which is often a bullish sign.</p>
<p>Building on these views&nbsp;that investors enjoyed the rally, here&#39;s what investors can now keep in mind moving forward and decide whether there is still further upside left in Taiwan Semiconductor stock. To start with revenue, the&nbsp;<a href="https://pr.tsmc.com/english/news/3180" rel="noopener" target="_blank">company&#39;s earnings press release</a> shows a jump of 39% over the past 12 months.</p>
<p>Then, investors can lean on the fact that the company&#39;s net income jumped by 54% during the quarter to significantly boost potential valuation targets from Wall Street analysts. But that&#39;s all in the past; in order to accurately predict the stock&#39;s value, investors need to look into the future.</p>
<p>Easing some of the fears of demand from the industry, the company&#39;s CEO said, &quot;Demand is real, and I believe it&#39;s just the beginning,&quot; speaking of other peers in the space like NVIDIA. These words were quantified further after the statement, though management guidance to blow most expectations out of proportion.</p>
<p>Revenue projections, even after a 54% jump over the past quarter, are still expected to outpace current guidance projections. For the next quarter, Taiwan Semiconductor management expects to deliver up to $26.9 billion in revenues compared to the estimate of $24.9 billion.</p>
<p>Not only is revenue expected to rise by another double-digit rate, but here&#39;s where valuations can be boosted in the coming months. Gross margins are guided to land nearer to 57% against the former consensus of 54.7%, which speaks to the state of pricing power present in the industry as demand outpaces supply to help costs and prices.</p>
<h3><strong>Wall Street Weighs In On Taiwan Semiconductor Stock: What Investors Can Expect Next</strong></h3>
<p>Recently, analysts at Needham &amp; Co. decided to reiterate their &quot;Buy&quot; rating on Taiwan Semiconductor stock on the day of earnings. Still, their valuations seem a bit out of touch. They see the stock going to $210, which is still roughly a dollar lower than where it rallied.</p>
<p>More significant is the previous price target set by those at Susquehanna in August 2024. Those analysts saw a &quot;Positive&quot; rating for the stock, this time boosting their targets and <a href="https://www.marketbeat.com/stocks/NYSE/TSM/forecast/">valuation up to $250 a share</a> to call for a further 18.5% upside from where the stock trades today.</p>
<p>Realizing that the demand trends might favor more profitability and margins in the industry, bearish traders decided to step away from the market during the past quarter. Taiwan Semiconductor stock&#39;s short interest has declined from $5.6 billion at the peak of last quarter <a href="https://www.marketbeat.com/stocks/NYSE/TSM/short-interest/">to $4.5 billion today</a>.</p>
<p>As the stock rallies by double-digits this week, more short sellers might be forced to cover their positions and add additional buying pressure to a stock whose bullish momentum seems to just be getting started.</p>
<p>The article &quot;<a href="https://www.marketbeat.com/originals/taiwan-semiconductor-soars-on-earnings-with-more-room-to-run/">Taiwan Semiconductor Soars on Earnings With More Room to Run</a>&quot; first appeared on MarketBeat.</p>


Tech

General

ASML

NVIDIA

Taiwan Semiconductor Soars On Earnings With More Room To Run

<p>The Procter &amp; Gamble Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pg#NYSE">PG</a>) issued its fiscal 2025 first-quarter earnings report on Friday, missing sales and net income estimates but topping adjusted profit estimates.&nbsp;</p>
<h3>Fiscal First Quarter Highlights</h3>
<p>For the quarter ended on September 30th, P&amp;G reported&nbsp;net sales<strong>&nbsp;</strong>dropped&nbsp;1% to $21.74 billion</p>
<p>Putting away&nbsp;&nbsp;foreign exchange, acquisitions and divestitures,&nbsp;organic revenue grew 2% helped by higher prices. However, volume was flat, which is a better reflection of sales. While in the U.S., P&amp;G&rsquo;s volume grew in eight of its 10 categories, Greater China&nbsp;told an entirely diferent story with both its hair care and oral care segments reporting volume declines.&nbsp;</p>
<p>Overall, health care and baby, feminine and family care divisions all reported 1% volume declines, the beauty business experienced a volume decline of 2%, while organic sales of the skin care segment tumbled more than 20%. Supported by innovation, grooming division was a rare bright spot with volume growth of 4%.&nbsp;Fabric and home care reported a mild volume rise of 1%.&nbsp;</p>
<p>Getting down to the bottom line, net income attributable to the company amounted to $3.96 billion, or $1.61 per share, with adjusted earnings per share amounting to $1.93 per share.</p>
<p>After several price hikes over the last few years, P&amp;G has seen demand for its products drop. The last quarter was the first time in more than two years that P&amp;G experienced an increase in volume, but it was apparently short-lived.&nbsp;With the falling&nbsp;global birth rate continues to drop, P&amp;G has been trying to push consumers to buy more expensive baby care items&nbsp;but organic sales of the baby care segment fell by mid-single digits as that strategy cannot always make up for the volume decline.&nbsp;</p>
<p>P&amp;G remains on track to deliver its guidance.</p>
<p>P&amp;G reiterated its fiscal 2025&nbsp;guidance, expecting revenue growth between&nbsp;2% and 4% and net earnings per share ranging from $6.91 to $7.05. But, P&amp;G CFO&nbsp;CFO Andre Schulten noted that the Chinese market will continue to be weak for quarters to come.&nbsp;The macroeconomic environment in the U.S. that accounts for almost half of total sales remains challenging with uncertainty pushing consumers to discount-offering rivals and cheaper brands. Its rival in packaged foods manufucating, Nestle S.A. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/nsrgy#OTC">NSRGY</a>) lowered its annual sales outlook. Nestle expects the weak demand environment to continue. After reporting dissapointing sales, Nestle announced changes corporate structure changes, aiming to streamline its operating structure. With the pandemic and the war in Ukraine, the packaged foods industry is not alone in struggling with soaring costs as prices of everything from raw materials to packaging continues to go through the roof. Even a Swiss giant like Nestle is dealing with a very painful and unprecedented reset as just like P&amp;G, it faces not only a demand slowdown&nbsp;but a significantly weakened consumer in the eyes of unprecedented uncertainty that has been lingering for quite some time, without any signs of going away.</p>
<p><em>DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.</em></p>
<p class="contributor-disclaimer"><em>This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.</em></p>


Nestle Sponsored representing Registered Shares Series B

NSRGY

Procter & Gamble Faces A Weakened Demand In Both The U.S. And China

<p>In the winter of 2023, combat medic <strong>Ihor Kholodylo</strong> faced a life-altering event on Ukraine&#8217;s eastern front. A shell from a Russian tank struck his medical evacuation van, leaving him severely injured. Though Kholodylo survived, the psychological toll was profound. Despite healing from physical injuries, he was left with a debilitating stutter, a symptom of post-traumatic stress disorder (PTSD).</p>
<p>As Kyiv Post <a href="https://www.kyivpost.com/post/40573">reported</a>, Kholodylo, a psychologist by profession, recognized that traditional <a href="https://www.benzinga.com/topic/ptsd">PTSD</a> treatments, such as talk therapy, would take too long. His search for faster relief led him to an emerging treatment: <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine-assisted therapy</a> (KAP). Conducted at the <strong>Expio Clinic</strong> in Kyiv, Kholodylo&#8217;s experience with ketamine revealed buried traumas from his time on the frontlines. After several sessions, his stutter vanished.</p>
<p>&#8220;I needed something different and more direct,&#8221; Kholodylo explained. "The concept [of ketamine] made sense to me, it helped access the unconscious."</p>
<p>Kholodylo is now advocating for wider access to KAP for Ukrainian veterans. He envisions <a href="https://www.benzinga.com/topic/ketamine">ketamine</a> not only as a treatment for PTSD but as a preventive measure for soldiers between combat assignments.</p>
<h3 class="wp-block-heading"><strong>Ketamine's Role In PTSD Treatment</strong></h3>
<p>Ketamine, once known as an anesthetic, <a href="https://www.benzinga.com/markets/cannabis/24/05/38652184/ketamine-assisted-psychotherapy-offers-hope-in-the-treatment-of-chronic-pain-and-depression-here">has shown significant promise</a> for treating mental health conditions like PTSD. Unlike traditional antidepressants, which can take weeks to show results, ketamine works within hours, providing immediate relief from anxiety, depression and traumatic symptoms. According to <a href="https://www.benzinga.com/partner/biotech/24/05/38941052/revolutionizing-mental-healthcare-with-the-rise-of-ketamine-and-psychedelic-therapies">several studies</a>, ketamine acts on the brain's glutamate system, which helps reset abnormal neural activity, a key factor in PTSD.</p>
<p><strong>Dr. Vladislav Matrenitsky</strong>, founder of the Expio Clinic, emphasizes the scientific foundation of ketamine's effectiveness. "We know why it works in terms of brain chemistry and physiology," he says, explaining that ketamine restores neural functioning and helps patients process trauma without re-traumatization.</p>
<p>At Expio, more than 300 clients have undergone KAP since 2018, with military veterans becoming an increasing portion of the patient base following the <a href="https://www.benzinga.com/topic/russia-ukraine-war">2022 Russian invasion</a>. Matrenitsky reports that 70% of patients experience improvement, with ketamine showing a 50% greater impact than conventional therapy.</p>
<h3 class="wp-block-heading"><strong>Scaling Ketamine For Ukrainian Veterans</strong></h3>
<p><strong>Heal Ukraine Trauma</strong> <strong>(HUT)</strong>, an NGO focused on mental health, has trained eight Ukrainian psychologists and psychiatrists in group ketamine therapy. According to HUT executive director <strong>Elise Wilson</strong>, the group model allows more veterans to be treated, fostering a sense of community among them.</p>
<p>"The group therapy model not only allows for more individuals to be treated but also creates a supportive network that extends beyond the therapy sessions," Wilson told the Kyiv Post. HUT plans to train 64 more practitioners in 2025, hoping to eventually treat up to 9,600 veterans annually.</p>
<p>While KAP shows promise, advocates stress that ketamine is not a &#8220;silver bullet.&#8221; Wilson emphasizes that ketamine should be integrated into a comprehensive care framework that includes psychotherapy and long-term support.</p>
<h3 class="wp-block-heading"><strong>A Path To National Recovery</strong></h3>
<p>As Ukraine grapples with the scars of war, <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted therapy</a> offers new hope. <strong>Oleh Orlov</strong>, chair of the <strong>Ukrainian Psychedelic Research Association</strong>, views this approach as not just a medical advancement but a crucial step toward national recovery.</p>
<p>"For Ukraine, this represents not just a medical advancement but a crucial step towards emotional resilience," says Orlov.</p>
<p>To this end, <a href="https://www.benzinga.com/topic/volodymyr-zelensky"><strong>President Volodymyr Zelensky</strong></a>, <a href="https://www.benzinga.com/markets/cannabis/24/02/37167633/ukraines-zelensky-signs-medical-cannabis-bill-to-help-those-suffering-from-trauma-amid-war-with-">signed a bill on medical cannabis</a> early this year. But, although several studies have <a href="https://www.benzinga.com/markets/cannabis/23/11/35735382/veterans-day-can-psychedelic-treatment-help-stem-ptsd-related-suicides-among-veterans">confirmed the potential</a> of cannabis and psychedelics to treat PTSD, the country&#8217;s law <a href="https://www.benzinga.com/markets/cannabis/24/08/40556985/ptsd-patients-could-be-left-behind-as-ukraines-medical-marijuana-law-takes-effect-and-more-canna">does not explicitly list this condition</a> for which the plant can be prescribed, as the Ministry of Health refused calls to include it.&nbsp;</p>
<p><br />&#8220;We worked hard to include more conditions, but the Ministry of Health has taken a conservative approach,&#8221; said <strong>Hanna Hlushchenko</strong>, founder of the <strong>Ukrainian Cannabis Consulting Group</strong>. &#8220;For example, we pushed for the inclusion of conditions like insomnia and PTSD, but these were not added"</p>
<p><em>Cover image made with AI</em></p>


Psychedelics

Eurozone

Ukraine's Military Veterans Turn To Ketamine For PTSD Treatment As Advocacy Grows

<ul>
<li>Under Armour, a Maryland-based sports apparel company, was experiencing rapid growth at the turn of the last decade.</li>
<li>In April 2016, Under Armour reported first-quarter earnings, marking its 24th consecutive quarter of over 20% revenue growth.</li>
<li>The company also predicted strong sales growth in the upcoming quarters.</li>
<li>However, in January 2017, Under Armour announced disappointing quarterly earnings and the unexpected resignation of its CFO, causing the stock to drop by more than 25% in just one day.</li>
<li>Shortly after, shareholders filed a lawsuit, claiming the company misled them about its financial health and revenue growth.</li>
<li>Under Armour recently agreed to pay a massive $434 million settlement to investors to resolve the lawsuit. Affected investors can now <a href="https://11thestate.com/cases/underarmour-investor-settlement">file a claim</a> to receive the payout.</li>
</ul>
<h3 class="wp-block-heading has-medium-font-size"><strong>Overview</strong></h3>
<p>During Under Armour, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) expansion phase, the company claimed it could sustain a 20% revenue growth for a long time. However, it later emerged that management hid issues with meeting these expectations due to declining demand and used questionable accounting practices to cover up the company's struggles. These claims were also backed by a separate investigation from the Securities and Exchange Commission. After years of legal disputes, the company has agreed to pay $434 million to affected shareholders over this situation.</p>
<h3 class="wp-block-heading has-medium-font-size"><strong>Background</strong></h3>
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p><cite><em>"Our first quarter revenues grew 30%, with the growth coming from every facet of our business. And to be clear, that 30% number was no accident. When Stephen Curry decided to average 30 points this season to take the scoring title while wearing the number 30, we thought that putting up 30% growth on our end was the best way for us to demonstrate our pride and support of Stephen and the Warriors."</em> – Kevin Plank (Q1 2016 earnings call)</cite></p></blockquote>
<p>Kevin Plank, the company's founder, served as the CEO during this growth phase of the company. The growth of the company was fueled by sportswear, which has been one of the company's principal products since its establishment in 1996. By 2014, the company reached a peak as it became the second-largest sportswear company in the United States by revenue. Committed to being positioned in the market at the high end and leveraging its cutting-edge technology on fabrics, Under Armour achieved 26 consecutive quarters of 20%+ YoY revenue growth from Q2 2010 to Q3 2016. The company's management promised a 20% growth in the upcoming quarters as well. However, Under Armour fell short of these expectations and, compounding the issue, the company&#8217;s CFO also left. These events shook investor confidence, causing the stock price to drop over 25% in a single day in January 2017.</p>

<h3 class="wp-block-heading has-medium-font-size"><strong>Under Armour's Rosy Promises Met With Reality</strong></h3>
<p>After the third quarter of 2016, Under Armour began to see a significant decline in demand, particularly in its most profitable segment at the time: apparel. The company struggled to keep up with the rising &#8220;athleisure&#8221; trend, leading consumers to seek alternatives from its competitors.</p>
<p>In January 2017, when Under Armour announced its Q4 2016 earnings, investors were disappointed by weaker-than-expected sales growth. To make matters worse, CFO Lawrence Molloy also left the company, leading to a 26% drop in stock price on January 31, 2017. As shown below, Under Armour&#8217;s revenue growth never fully recovered to the levels seen between 2010 and 2016, highlighting that the company's business was already weakening in 2016, despite its continued promises of growth.</p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="626" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184219/tg_image_1594745250-1-1024x626.png" alt="" class="wp-image-2549" style="width:674px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184219/tg_image_1594745250-1-1024x626.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184219/tg_image_1594745250-1-300x184.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184219/tg_image_1594745250-1-768x470.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184219/tg_image_1594745250-1.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>Under Armour&#8217;s financial troubles, despite management&#8217;s promises, led to a shareholder lawsuit in 2017. While Under Armour asserted strong demand for its products, signs of trouble were apparent, such as the bankruptcy of The Sports Authority. The lawsuit highlighted the company&#8217;s inaccurate claims of achieving 20% YoY revenue growth amid rising inventory levels. This situation forced Under Armour to lower its prices significantly, damaging its reputation as a premium sports apparel brand while competitors like Nike maintained higher prices.</p>
<p>The suit also raised concerns about Under Armour&#8217;s accounting practices, with accusations that the company inflated its financial performance by pulling revenue from future quarters. This led to the SEC investigation, which discovered that Under Armour had not disclosed its strategy of accelerating $408 million in orders for the second half of 2015, further casting doubt on its financial reporting.</p>
<p>The company's former executives later revealed that Under Armour frequently pressured retailers to take products early and shifted goods meant for factory stores to off-price chains to boost end-of-quarter sales. These tactics, along with other questionable practices, helped the company maintain its sales growth streak.</p>
<p>After the investigation, Under Armour was charged with securities fraud for withholding key information in its SEC filings.&nbsp; In 2021, to settle the case with the SEC, Under Armour agreed to a payment of $9 million.&nbsp;</p>
<p>These financial missteps have had a lasting impact. After reaching a high of over $50 in 2015 amid strong growth and rosy promises, once a high-flying stock, UAA is currently trading at around $8.50. Under Armour stock has lost more than 74% of its market value in the last 10 years.</p>
<p><figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="852" height="392" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184420/image-14.png" alt="" class="wp-image-2550" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184420/image-14.png 852w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184420/image-14-300x138.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/18184420/image-14-768x353.png 768w" sizes="(max-width: 852px) 100vw, 852px" /></figure></p>
<h3 class="wp-block-heading has-medium-font-size"><strong>Resolving The Case</strong></h3>
<p>Under Armour continues to face financial challenges, reporting a 3% YoY decline in revenue for the most recent financial year. Its operating income has fallen from $408.5 million in 2015 to just $221.5 million in the past year, highlighting difficulties in staying profitable amid increasing competition.</p>
<p>Despite these issues, Under Armour&#8217;s directors and management have consistently denied any violations of securities laws, asserting that their actions were normal and lawful. They claim that no material misrepresentations or omissions were made in their filings. Mehri Shadman, the company&#8217;s chief legal officer and corporate secretary, further clarified the management&#8217;s position:&nbsp;</p>
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<p><cite><em>"We firmly believe that our sales practices, accounting practices, and disclosures were appropriate, and deny any wrongdoing in this case."</em>&nbsp;</cite></p></blockquote>
<p>In a positive turn for shareholders facing significant losses, Under Armour reached a settlement in June 2024, agreeing to pay $434 million to affected investors. If you invested in Under Armour between 2015 and 2019, you can <a href="https://11thestate.com/cases/underarmour-investor-settlement">claim part</a> of this settlement to recover some of your losses.</p>


The Price Of Overpromising: Under Armour's Legal Battle

<p>The five years after Canada legalized recreational cannabis have produced enough data for researchers to look at important questions like how <a href="https://www.benzinga.com/markets/cannabis/24/06/39277643/legal-weed-less-crime-fbi-data-shows-surprising-benefits-of-cannabis-legalization">organized crime</a> is affected by legalization, or not.</p>
<p>A recent <a href="https://onlinelibrary.wiley.com/doi/full/10.1111/soin.12619">study</a>, published in <strong>Sociological Inquiry</strong>, explores how the shift to a legal market has reshaped criminal enterprises once heavily involved in the illicit cannabis trade.</p>
<h3 class="wp-block-heading">Key Findings On Organized Crime &amp; Cannabis</h3>
<p>The research, conducted by scientists <strong>Martin Bouchard</strong>, <strong>Naomi Zakimi</strong> -of <strong>Simon Fraser University</strong>-, and Benoît Gomis -of the <strong>University of Toronto</strong>&#8211; shows that the <a href="https://www.benzinga.com/markets/cannabis/24/08/40558227/cannabis-sales-in-canada-decline-sharply-whats-behind-the-drop">legal cannabis market</a> now dominates in Canada, <strong>accounting for over 71% of household expenditures on cannabis as of 2023</strong>. However, nearly 29% of the market still belongs to <a href="https://www.benzinga.com/markets/cannabis/24/09/40837305/new-partnership-targets-unlicensed-cannabis-shops-in-new-york-heres-how">unlicensed sellers</a>.</p>
<p>Some of the study's most notable findings include:</p>
<ol>
<li><strong>A Shrinking Illicit Market</strong>: Legal cannabis sales have steadily increased since legalization, gradually cutting into the black market.</li>
<li><strong>Organized Crime&#8217;s Resilience</strong>: Criminal organizations are adapting, either by diverting legal cannabis into the unlicensed market or shifting their operations to illegal drugs.</li>
<li><strong>Consumer Challenges</strong>: High prices, inconsistent quality, and limited accessibility in the legal market continue to drive some consumers toward cheaper, unlicensed alternatives.</li>
<li><strong>Cross-Border Smuggling</strong>: Despite legalization, some unlicensed products are smuggled out of Canada into markets abroad, particularly in the U.S.</li>
<li><strong>Shifting Criminal Focus</strong>: With cannabis becoming less profitable, many criminal groups are focusing on more dangerous drugs like opioids.</li>
</ol>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/06/39277643/legal-weed-less-crime-fbi-data-shows-surprising-benefits-of-cannabis-legalization">Legal Weed = Less Crime: FBI Data Shows Surprising Benefits Of Cannabis Legalization</a></strong></p>
<h3 class="wp-block-heading">Methods And Indicators</h3>
<p>To draw these conclusions, the researchers conducted a comprehensive review of more than 5,000 sources, including academic papers, media reports and government publications.</p>
<p>The key indicators used to assess the impact of cannabis legalization on organized crime include several metrics, such as price comparison between legal and illicit cannabis markets, supply-demand balance and cash circulation.</p>
<p>Lower legal cannabis prices tend to pull consumers away from illegal sources, so price monitoring is crucial. Cannabis demand estimates and legal supply are also analyzed to measure how well the legal market meets consumption needs, which could reduce reliance on the illicit market. Other indicators include tracking <a href="https://www.benzinga.com/markets/cannabis/24/01/36685934/why-is-the-illicit-cannabis-market-still-outselling-cool-legal-weed-dispensaries-let-me-count-th">illicit cannabis</a> seizures by law enforcement, examining criminal justice data for organized crime ties and analyzing cash circulation as an indicator of illegal market transactions.</p>
<p>These methods, along with interviews and internal documents, provide a more nuanced understanding of how organized crime has responded to legalization.</p>
<ul>
<li><strong><em>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;</em></strong><a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener"><strong><em>here</em></strong></a><strong><em>. If you're serious about the business, you can't afford to miss out.</em></strong></li>
</ul>
<h3 class="wp-block-heading">Recommendations For Policy Makers</h3>
<p>One key finding is that the link between <a href="https://www.benzinga.com/markets/cannabis/24/08/40591338/canadas-cannabis-growth-slowed-due-to-federal-gov-inaction-key-industry-leader-says">unlicensed</a> and licensed cannabis is persistent and complex.</p>
<p>&#8220;Policies and law enforcement interventions aiming to address the illicit cannabis trade in Canada may indeed have consequences on <em>legal</em> cannabis production, sales, and consumption as well. The legal market may need to compete by learning from the consumer preferences established in the illegal market.&#8221;</p>
<p>Thus there&#8217;s a need for a comprehensive approach.</p>
<p>&#8220;Regulators and politicians would do well to measure expectations: the illegal activities along cannabis supply chains will persist and eliminating them altogether is an unrealistic goal,&#8221; the researchers add.</p>
<ul>
<li><strong>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/41034042/fbi-report-over-200-000-people-were-arrested-for-cannabis-related-violations-in-2023-how-is-that">FBI Report Over 200,000 People Were Arrested For Cannabis-Related Violations In 2023: How Is That Possible?</a></strong></li>
</ul>
<p><em>Cover: Courtesy of the California Department of Cannabis Control.</em></p>


Politics

Legal

How Does Cannabis Legalization Affect Organized Crime? New Research Sheds Light

<p>In the preceding three months, 8 analysts have released ratings for Webster Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Webster Finl, revealing an average target of $57.62, a high estimate of $63.00, and a low estimate of $51.00. This current average reflects an increase of 4.29% from the previous average price target of $55.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729285270_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Webster Finl among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$59.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$63.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$54.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Webster Finl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Webster Finl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Webster Finl's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Webster Finl's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WBS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Webster Finl analyst ratings.</strong></a></p>
<h2>About Webster Finl</h2>
<p>Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.</p>
<h3>Webster Finl: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Webster Finl displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>7.97%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Webster Finl's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>28.45%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.17%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Webster Finl's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.24%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Webster Finl's debt-to-equity ratio is below the industry average. With a ratio of <b>0.45</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Navigating 8 Analyst Ratings For Webster Finl

<p>In the preceding three months, 14 analysts have released ratings for M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for M&amp;T Bank, revealing an average target of $203.64, a high estimate of $228.00, and a low estimate of $165.00. This upward trend is evident, with the current average reflecting a 12.65% increase from the previous average price target of $180.77.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729285217_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of M&amp;T Bank by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$190.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$218.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$216.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$228.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$208.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Bill Carcache</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$210.00</td>
<td>-</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$210.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$210.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$165.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$183.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$188.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Frank Schiraldi</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$164.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to M&amp;T Bank. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of M&amp;T Bank compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for M&amp;T Bank's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of M&amp;T Bank's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MTB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on M&amp;T Bank analyst ratings.</strong></a></p>
<h2>Get to Know M&amp;T Bank Better</h2>
<p>M&amp;T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.</p>
<h3>Financial Insights: M&amp;T Bank</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> M&amp;T Bank's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>1.3%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> M&amp;T Bank's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>28.9%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.58%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> M&amp;T Bank's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.32%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> M&amp;T Bank's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.54</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


M&T Bank Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)

WIIM

The Cigna Group shares are trading lower after a report suggesting the company has resumed merger discussions with Humana after the conversation ended last year.

<p>Canadian cannabis edibles company <strong>City View Green Holdings Inc.</strong> (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CVGR#CSE">CVGR</a>) (OTCPK:CVGRF) announced Thursday it <strong>plans</strong><strong> to raise gross proceeds of up to </strong><strong>CA</strong><strong>$1 </strong><strong>million</strong><strong>($730,000) </strong><strong>through a non-brokered private placement of up to 100 </strong><strong>million </strong><strong>units at a price of </strong><strong>CA</strong><strong>$0.01 per </strong><strong>u</strong><strong>nit.</strong></p>
<p>Under the placement, each unit will include one company share and half a warrant. Two halves make a full warrant, allowing the holder to buy one company share at CA$0.05 per share for up to three years after the issue date. If the average closing price of the company&#8217;s shares on the CSE equals or exceeds CA$0.055 for 10 consecutive trading days, starting one year after the closing, the company may shorten the warrant&#8217;s expiry date to 30 days after notifying holders.</p>
<p>City View Green plans to use the net proceeds from the placement for general working capital purposes.</p>
<p>The non-brokered private placement is subject to regulatory approvals. The company will pay finders&#8217; fees to eligible finders in connection with the private placement, in compliance with applicable securities laws and CSE policies. The securities issued in the private placement will be subject to a four-month and one-day hold period, in accordance with Canadian securities laws.</p>
<p><strong>Read Also: </strong><a href="https://www.benzinga.com/general/biotech/24/10/41394513/sold-out-before-hitting-shelves-why-did-ayr-wellness-snatch-up-this-local-cannabis-brand"><strong>Sold Out Before Hitting Shelves: Why Did AYR Wellness Snatch Up This Local Cannabis Brand?</strong></a></p>
<ul>
<li><em><strong>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</strong></em></li>
</ul>
<p>Additionally, City View Green entered into a marketing and consulting agreement with the arm&#8217;s-length marketing firm <strong>Outside The Box Capital Inc.</strong> of Oakville, Ontario, to provide marketing and investor relations services, including social media and online media distribution. In connection with this engagement, starting on Oct. 15, 2024 and ending on Feb. 15, 2025, the company will pay OTBC a cash fee of $25,000 per month to a maximum of $75,000 over the term plus applicable taxes.</p>
<p>In April, City View Green announced it has <a href="https://www.newsfilecorp.com/release/205820/City-View-Green-Holdings-Inc.-Exits-Retail-Cannabis-Through-Ownership-in-Budd-Hutt-Announces-Director-Resignation">exited the retail cannabis space</a> through ts ownership in Budd Hutt, which relinquished its last two licenses and no longer operates in the Province of Alberta.</p>
<p>In November 2023, the company revealed it plans to review its strategy following June's working capital deficiency of almost CA$3.9 million and accumulated deficit of CA$44 million, <a href="https://www.greenmarketreport.com/city-view-green-seeks-c1m-after-alberta-retail-exit/">writes</a> Green Market's Adam Jackson. City View Green is yet to generate any revenue from its edibles operations.</p>
<h2 class="wp-block-heading"><strong>Price Action</strong></h2>
<p><strong>City View Green shares closed Friday&#8217;s market session flat at $0.0051 per share.</strong></p>
<p><strong><br />Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41388261/revolutionizing-cannabis-edibles-ascends-new-thc-cannabinoid-blends-now-available-in-this-east-c"><strong>Revolutionizing Cannabis Edibles: Ascend&#8217;s New THC-Cannabinoid Blends Now Available In This East Coast Market</strong></a></li>
</ul>
<p><em>Photo: Courtesy of&nbsp;HTWE&nbsp;via Shutterstock&nbsp;</em></p>


CSE:CVGR

CVGRF

Canadian Cannabis Edibles Producer City View Green To Raise $730K Via Private Placement

Humana shares are trading higher after a report suggesting Cigna has resumed merger discussions with the company after the conversation ended last year.

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Citigroup</strong>.</p>
<p>Looking at options history for Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) we detected 41 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 39% of the investors opened trades with bullish expectations and 51% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $1,005,393 and 36, calls, for a total amount of $2,928,597.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $42.5 to $75.0 for Citigroup during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Citigroup options trades today is 14959.83 with a total volume of 47,452.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Citigroup's big money trades within a strike price range of $42.5 to $75.0 over the last 30 days.</p>
<h3>Citigroup Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729284335_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$4.95</td>
<td>$62.50</td>
<td>$814.7K</td>
<td>14.6K</td>
<td>3.2K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.55</td>
<td>$13.5</td>
<td>$13.5</td>
<td>$50.00</td>
<td>$472.5K</td>
<td>39.1K</td>
<td>352</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.3</td>
<td>$13.25</td>
<td>$13.25</td>
<td>$50.00</td>
<td>$198.7K</td>
<td>39.1K</td>
<td>761</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.3</td>
<td>$13.25</td>
<td>$13.25</td>
<td>$50.00</td>
<td>$198.7K</td>
<td>39.1K</td>
<td>611</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$15.8</td>
<td>$15.7</td>
<td>$15.8</td>
<td>$47.50</td>
<td>$145.3K</td>
<td>23.9K</td>
<td>2.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Citigroup</h3>
<p>Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.</p>
<p>In light of the recent options history for Citigroup, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Citigroup Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 13,599,539, with C's price down by -1.75%, positioned at $62.85.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 89 days.</li>
</ul>
<h3>What Analysts Are Saying About Citigroup</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $82.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a In-Line rating for Citigroup, targeting a price of $64.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on Citigroup, maintaining a target price of $78.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Citigroup with a target price of $86.<br />
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Citigroup, maintaining a target price of $92.<br />
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Citigroup with a target price of $91. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Citigroup, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Smart Money Is Betting Big In Citigroup Options

<p>Financial giants have made a conspicuous bearish move on United Airlines Holdings. Our analysis of options history for United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) revealed 59 unusual trades.</p>
<p>Delving into the details, we found 42% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 18 were puts, with a value of $4,003,104, and 41 were calls, valued at $5,898,846.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $38.0 to $90.0 for United Airlines Holdings during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for United Airlines Holdings's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of United Airlines Holdings's whale activity within a strike price range from $38.0 to $90.0 in the last 30 days. </p>
<h3>United Airlines Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729284330_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$9.15</td>
<td>$9.1</td>
<td>$9.15</td>
<td>$75.00</td>
<td>$935.2K</td>
<td>5.6K</td>
<td>2.5K</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.3</td>
<td>$5.25</td>
<td>$5.25</td>
<td>$75.00</td>
<td>$368.5K</td>
<td>17.1K</td>
<td>2.2K</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$11.35</td>
<td>$11.2</td>
<td>$11.2</td>
<td>$65.00</td>
<td>$340.5K</td>
<td>6.5K</td>
<td>825</td>
</tr>
<tr>
<td>UAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$9.3</td>
<td>$9.15</td>
<td>$9.15</td>
<td>$75.00</td>
<td>$334.9K</td>
<td>5.6K</td>
<td>2.5K</td>
</tr>
<tr>
<td>UAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$5.25</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$75.00</td>
<td>$329.9K</td>
<td>17.1K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>
</p>
<h3>About United Airlines Holdings</h3>
<p>United Airlines is a major US network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large US peers.</p>
<h3>United Airlines Holdings's Current Market Status</h3>
<ul>
<li>With a volume of 8,318,667, the price of UAL is up 0.78% at $73.9. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 95 days.</li>
</ul>
<h3>What The Experts Say On United Airlines Holdings</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $83.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Susquehanna has decided to maintain their Positive rating on United Airlines Holdings, which currently sits at a price target of $70.<br />
&#x2A; An analyst from Jefferies has decided to maintain their Buy rating on United Airlines Holdings, which currently sits at a price target of $75.<br />
&#x2A; Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on United Airlines Holdings with a target price of $100.<br />
&#x2A; An analyst from Susquehanna has decided to maintain their Positive rating on United Airlines Holdings, which currently sits at a price target of $85.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for United Airlines Holdings, targeting a price of $88. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest United Airlines Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Behind the Scenes of United Airlines Holdings's Latest Options Trends

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Synopsys</strong>.</p>
<p>Looking at options history for Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) we detected 21 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 28% of the investors opened trades with bullish expectations and 33% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $423,980 and 16, calls, for a total amount of $811,190.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $420.0 and $610.0 for Synopsys, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Synopsys's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Synopsys's significant trades, within a strike price range of $420.0 to $610.0, over the past month.</p>
<h3>Synopsys Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729284326_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SNPS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$55.0</td>
<td>$50.8</td>
<td>$50.8</td>
<td>$420.00</td>
<td>$213.3K</td>
<td style="text-align: right;">80</td>
<td style="text-align: right;">42</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$63.3</td>
<td>$61.0</td>
<td>$61.0</td>
<td>$600.00</td>
<td>$91.5K</td>
<td style="text-align: right;">150</td>
<td style="text-align: right;">64</td>
</tr>
<tr>
<td>SNPS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$31.9</td>
<td>$31.4</td>
<td>$31.6</td>
<td>$510.00</td>
<td>$69.5K</td>
<td style="text-align: right;">103</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>SNPS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$31.9</td>
<td>$31.5</td>
<td>$31.5</td>
<td>$510.00</td>
<td>$63.0K</td>
<td style="text-align: right;">103</td>
<td style="text-align: right;">72</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$61.0</td>
<td>$60.0</td>
<td>$60.0</td>
<td>$600.00</td>
<td>$60.0K</td>
<td style="text-align: right;">150</td>
<td style="text-align: right;">116</td>
</tr>
</tbody>
</table>
</p>
<h3>About Synopsys</h3>
<p>Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.</p>
<p>Following our analysis of the options activities associated with Synopsys, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Synopsys Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 854,725, with SNPS's price up by 0.46%, positioned at $507.03.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 40 days.</li>
</ul>
<h3>What Analysts Are Saying About Synopsys</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $660.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Berenberg downgraded its rating to Buy, setting a price target of $660. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Synopsys, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


SNPS

Behind the Scenes of Synopsys's Latest Options Trends

<p><a href="https://www.bloomberg.com/news/articles/2024-10-18/cigna-resumes-merger-discussions-with-humana-after-talks-ended-last-year?srnd=phx-deals">https://www.bloomberg.com/news/articles/2024-10-18/cigna-resumes-merger-discussions-with-humana-after-talks-ended-last-year?srnd=phx-deals</a></p>
<p>&nbsp;</p>


'Cigna Resumes Merger Discussions With Humana After Talks Ended Last Year' - Bloomberg

Mondee Holdings, Inc. (MOND) 19th Annual Needham Technology, Media, & Consumer Conference (Transcript)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Generally, when the masses &ndash; including the market&rsquo;s heavy hitters &ndash; decide to bet against a security, it&rsquo;s best to avoid it. However, the unique nuances involved with shorting a company opens the door for the contrarian trade. To be sure, so-called short-squeeze stocks to buy are incredibly risky. Yet at the same time, they also present significant upside potential.</p>



<p>When you go long a company, you&rsquo;re obviously hoping that you can buy low and sell high. However, when you short an enterprise, you&rsquo;re aiming to sell high so that you can buy low later and profit from the difference. To initiate a pure short position requires first borrowing (setting aside the exception of naked short selling) the target stock from a broker.</p>



<p>That&rsquo;s where circumstances get interesting. If the underlying security falls in value, a short position can be incredibly lucrative. However, if shares rise, the bearish speculator ends up losing money. Not only that, no upside ceiling exists for any stock. Therefore, it&rsquo;s critical to cut losses early.</p>



<p>The panic to exit early is what creates the upside pressure undergirding short-squeeze stocks to buy. It&rsquo;s a risky business but it&rsquo;s oh so tempting.</p>



<h2>Nuvalent (NUVL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div><p>One of the most heavily targeted securities, <strong>Nuvalent</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuvl-stock-quote/"><strong>NUVL</strong></a>) falls under the biotechnology sphere. Specifically, it&rsquo;s a clinical-stage biopharmaceutical firm that engages in the development of therapies for patients with cancer. Notably, NUVL stock has gained 79% in the past 52 weeks. Since making its public market debut, the company gained around 330% of equity value.</p>



<p>That said, skeptics have entered the fray. Presently, NUVL represents one of the most targeted securities, with a <a href="https://fintel.io/ss/us/nuvl">short interest</a> of 20.29% of its float. Typically, any magnitude of short interest <a href="https://www.investopedia.com/terms/s/shortinterest.asp#:~:text=Yes.-,Short%20interest%20as%20a%20percentage%20of%20float%20above%2020%25%20is,indicates%20a%20very%20pessimistic%20sentiment.">above 20%</a> is considered to be high. Further, NUVL&rsquo;s short interest ratio &ndash; or the time required to unwind all bearish positions based on average trading volume &ndash; stands at 38.89 days to cover.</p>



<p>Based on that information, it seems like bad news for Nuvalent. However, the company could rank among the short-squeeze stocks to buy. Analysts rate NUVL a <a href="https://www.tipranks.com/stocks/nuvl/forecast">unanimous strong buy</a> with a $98.80 average price target. That implies a 26% upside potential.</p>



<p>Financially, experts anticipate that in fiscal 2025, sales could hit $$530,000, with a high-side view of $4.8 million. That would be massive as Nuvalent is presently a pre-revenue entity.</p>



<h2>Mondee (MOND)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/air-travel-1600-300x169.png" alt="Plane travel. Man standing in airport waiting for flight. travel stocks to buy"><div>Source: Olena Yakobchuk / Shutterstock</div></div><p>Based in Austin, Texas, <strong>Mondee</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mond-stock-quote/"><strong>MOND</strong></a>) falls under the consumer cyclical sector. Specifically, it provides travel services. The company&rsquo;s mainline business unit offers airline tickets through its platform. It also provides a Software as a Service (SaaS) model that facilitates corporate travel cost savings solutions. With people prioritizing vacations in the post-pandemic era, MOND stock should attract bullish attention.</p>



<p>However, that hasn&rsquo;t been the case at all. Since the beginning of the year, MOND slipped 18%. In the past 52 weeks, shares stumbled a staggering 75.5%. Not surprisingly, then, the bears began circling the waters. Short interest comes in at <a href="https://fintel.io/ss/us/mond">20.64% of the float</a>. Further, the short-interest ratio stands at 56.17 days to cover.</p>



<p>Still, not all hope is lost, at least for the optimists. Analysts rate Mondee a <a href="https://www.tipranks.com/stocks/mond/forecast">consensus moderate buy</a> with a $4.18 average price target, implying over 95% upside potential. Further, with the downside, MOND could be priced at a more enticing valuation. Shares trade at 0.69X trailing-year revenue. That&rsquo;s down from 1.21X in the fourth quarter of last year.</p>



<p>Experts also anticipate 14.8% growth in the top line to $255.09 million in fiscal 2024. So, MOND could be one of the short-squeeze stocks to buy.</p>



<h2>Zynex (ZYXI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/healthcare-1600-300x169.jpg" alt="Nurse holding a tablet with icons representing different aspects of healthcare and healthcare data representing CANO stock. Healthcare Tech Stocks. Healthcare Stocks to Buy"><div>Source: metamorworks / Shutterstock</div></div><p>Headquartered in Englewood, Colorado, <strong>Zynex</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/zyxi-stock-quote/"><strong>ZYXI</strong></a>) falls under the broader healthcare sector, specifically medical distribution. With its subsidiaries, Zynex designs, manufactures and markets medical devices to treat chronic and acute pain. Its primary focus is in the area of electrical stimulation for rehabilitative purposes. The business sounds incredibly relevant yet the market has other ideas.</p>



<p>Since the start of the year, ZYXI slipped almost 16%. The volatility has been pronounced in the past month, when shares gave up 13% of market value. Zynex has also gone nowhere in the trailing five years, thereby frustrating longtime stakeholders. As a result, the company&rsquo;s <a href="https://fintel.io/ss/us/zyxi">short interest</a> soared to 36.89% of the float. Also, the short-interest ratio jumped to 53.44 days to cover.</p>



<p>Obviously, that&rsquo;s not a great outcome. However, ZYXI could be one of the short-squeeze stocks to buy. It presently enjoys a consensus view of <a href="https://www.tipranks.com/stocks/zyxi/forecast">moderate buy</a>. Also, the price target stands at $18, implying 96% upside potential.</p>



<p>Financially, experts anticipate the company&rsquo;s sales in fiscal 2024 to rise to $226.95 million. If so, that would imply growth of 23.1%.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/06/3-short-squeeze-stocks-poised-for-a-jaw-dropping-rally/">3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Short-squeeze stocks represent one of the boldest forms of contrarianism available. Simply put, it&rsquo;s a showdown between the bears that are attempting to profit from the downturn of a public enterprise. In their minds, by eliminating weak players from the market, it improves Wall Street&rsquo;s &ldquo;gene pool,&rdquo; if you will. On the other end, the bulls can play the savior role.</p>



<p>What makes short-squeeze stocks so compelling, though, is the incentivization profile. On the pessimistic side, speculators make their money pocketing the difference between the borrowed securities selling price versus the subsequent buy-back price. If the latter is lower than the former, the trader picks up a profit. However, if the latter is higher, than the speculator incurs a loss.</p>



<p>Now, unlike other types of market losses, the red ink on a short trade is uncapped. That&rsquo;s because there&rsquo;s no limit to how high a security can rise. Therefore, a panic to cover bearish positions (by buying to close) can yield a dramatic lift in the share price, called a short squeeze. With that in mind, below are short-squeeze stocks to consider.</p>



<h2>Kadant (KAI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/07/short-squeeze-stocks-300x169.jpg" alt="Man squeezing water out of a rag representing FNGR stock. Short Squeeze Stocks"><div>Source: Alextype/Shutterstock.com</div></div><p>Operating in the specialty industrial machinery sector, <strong>Kadant</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/kai-stock-quote/"><strong>KAI</strong></a>) supplies various technologies and engineered systems worldwide. Primarily, the company focuses on fluid-handling systems and equipment, such as rotary joints and syphons. It also features other relevancies, including innovations in industrial automation and control. Still, KAI has fluctuated in market value.</p>



<p>Nevertheless, investors will want to keep close tabs on Kadant. According to Fintel, KAI stock carries a <a href="https://fintel.io/ss/us/kai">short interest of 12.32% of its float</a>. That&rsquo;s elevated but not intensely remarkable. However, the equity unit&rsquo;s short-interest ratio stands at nearly 33 days to cover. That&rsquo;s the number of trading sessions it would take for the bears to close out their short exposure.</p>



<p>If a panic materializes, the bears will be anxious to seal off their vulnerability. They&rsquo;re even more motivated to do this with Kadant, noting that KAI stock has gained 13% in the trailing month. In addition, the company is projected to see revenue growth of nearly 11% to $1.06 billion by year&rsquo;s end. It&rsquo;s one of the short-squeeze stocks to consider.</p>



<h2>AirSculpt Technologies (AIRS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/oversold-stocks-to-buy-300x169.jpg" alt="man in suit holding a tablet with graphic above showing oversold stocks to buy"><div>Source: undefined undefined / Getty Images</div></div><p>Operating in the medical care facilities industry, <strong>AirSculpt Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/airs-stock-quote/"><strong>AIRS</strong></a>) along with its subsidiaries provides body contouring procedure services. It offers its namesake solution, which is a next-generation body contouring protocol that removes unwanted fat and tightens skin. Best of all, the procedure is minimally invasive.</p>



<p>Still, many investors are skeptical about AIRS stock. Since the start of the year, shares tumbled more than 36%. As a result, the<a href="https://fintel.io/ss/us/airs"> short interest of AirSculpt comes in at 16.26% of its float</a>. However, the short-interest ratio is truly remarkable, standing at almost 56 days to cover. We&rsquo;re basically talking business days here so that&rsquo;s a lengthy period of vulnerability for the bears.</p>



<p>If AIRS stock starts shooting higher for whatever reason, a panic could easily materialize. It&rsquo;s worth pointing out that in the business week ended July 12, the equity gained more than 16%. In addition, analysts project that AirSculpt can post earnings per share of 24 cents this year. That&rsquo;s up from last year&rsquo;s loss of 8 cents. It&rsquo;s a candidate for short-squeeze stocks.</p>



<h2>Trupanion (TRUP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/trup1600-300x169.jpg" alt="a veterinarian holding a small white dog"><div>Source: Shutterstock</div></div><p>Falling under the specialty insurance segment, <strong>Trupanion</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/trup-stock-quote/"><strong>TRUP</strong></a>) in my opinion represents a clear-cut case for short-squeeze stocks. With its subsidiaries, Trupanion provides medical insurance for cats and dogs on a monthly subscription basis. What&rsquo;s enticing here is the fundamental catalyst: Americans (and citizens of other countries) love their pets.</p>



<p>It&rsquo;s too bad that Wall Street doesn&rsquo;t love TRUP stock. Since the beginning of this year, shares gained less than 2%. Over the past five years, it went nowhere if you had held throughout the entire period: TRUP lost a bit more than 9%. Still, what&rsquo;s intriguing here is that the equity&rsquo;s <a href="https://fintel.io/ss/us/trup">short interest</a> stands at nearly 33% of its float. Further, the short-interest ratio is 31.41 days to cover.</p>



<p>If you&rsquo;re an extreme contrarian, these figures may have you drooling. What you have is an extremely high short interest along with a blisteringly hot short ratio. You&rsquo;ve basically got the bears boxed in if the position moves against them. Analysts are calling for revenue to expand by 13.7% to $1.26 billion in fiscal 2024.</p>



<h2>Westrock Coffee (WEST)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/09/coffee_1600-300x169.jpg" alt="NUZE Stock. A photo of a cup of coffee and some coffee beans and a towel on a wooden table. Coffee stocks"><div>Source: Evgeny Karandaev/ShutterStock.com</div></div><p>Falling under the consumer defensive space, <strong>Westrock Coffee</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/west-stock-quote/"><strong>WEST</strong></a>) operates in the packaged foods industry. <a href="https://finance.yahoo.com/quote/WEST/profile/">Per its public profile</a>, Westrock is an integrated coffee, tea, flavors, extracts and ingredients provider. It mainly serves the U.S. though it also covers other international markets. With the growing demand for coffee worldwide, WEST stock should be intriguing for many investors.</p>



<p>Unfortunately, Wall Street doesn&rsquo;t have much love for Westrock. Since the beginning of January, shares lost about 2% of equity value. In the past 52 weeks, they&rsquo;re down 8%. Those aren&rsquo;t great statistics. At the same time, contrarian investors should consider the bearish profile. Short interest stands at a whopping 54.85%. That&rsquo;s extreme and then some. Also, the short ratio hits 33.27 days to cover.</p>



<p>Again, what we have here is a situation where the bears are locked in. If the position moves against them, a big panic can materialize. After all, 33 business days is a long time. Plus, experts project 9.4% sales growth to $945.67 million this year. It&rsquo;s one of the short-squeeze stocks to consider.</p>



<h2>Mondee Holdings (MOND)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/air-travel-1600-300x169.png" alt="Plane travel. Man standing in airport waiting for flight. travel stocks to buy"><div>Source: Olena Yakobchuk / Shutterstock</div></div><p>Operating in the consumer cyclical sector, <strong>Mondee Holdings</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mond-stock-quote/"><strong>MOND</strong></a>) specifically covers the travel services realm. <a href="https://finance.yahoo.com/quote/MOND/profile/">Per its corporate profile</a>, Mondee operates as a travel technology firm for the leisure travel space. Primarily, the company focuses on the sale of airline tickets through its platform. Thanks to people prioritizing their vacation time post-pandemic, MOND stock should be intriguing.</p>



<p>However, the market has had a tough time deciphering what the underlying business is all about. On a year-to-date basis, MOND incurred a loss of more than 3%. Further, the trading action has been incredibly choppy throughout 2024 so far. Still, MOND could attract contrarians with its short interest of just under 21% of its float. Further, the short interest ratio stands at 42.58 days to cover.</p>



<p>As with so many of the other short-squeeze stocks on this list, an upside panic can lead to more upside as the bears rush to cover their short positions. Experts also see Mondee hitting $255.09 million in sales for fiscal 2024, implying 14.8% growth from last year.</p>



<h2>scPharmaceuticals (SCPH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div><p>Falling under the biotechnology space, <strong>scPharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/scph-stock-quote/"><strong>SCPH</strong></a>) engages in the development and commercialization of various pharmaceutical products. Its lead <a href="https://finance.yahoo.com/quote/SCPH/profile/">product candidate is Furoscix</a>, which aims to treat congestion due to fluid overload in adults with chronic heart failure and kidney disease. Given the <a href="https://www.cdc.gov/pcd/issues/2024/23_0267.htm#:~:text=Over%20the%20past%202%20decades,at%20least%205%20(5).">rise of incidences of chronic disease</a>, scPharmaceuticals should &ldquo;benefit&rdquo; (for lack of a better word) from this dynamic.</p>



<p>However, the market seems to have other ideas. Since the start of the year, SCPH stock incurred a loss of more than 29%. In the past 52 weeks, it&rsquo;s down almost 47%. Still, this could be a case of bad news being good news, especially for contrarians. <a href="https://fintel.io/ss/us/scph">The short interest of SCPH stands at 36% of its float</a>. Also, the short-interest ratio clocks in at 50.5 days to cover.</p>



<p>If shares start flying higher, the bears could be locked in. Therefore, the contrarian bulls are possibly licking their lips. Analysts believe that the biotech could post sales of $39.34 million this year. If so, that would imply a growth rate of 189.4%. This is one of the more tempting short-squeeze stocks.</p>



<h2>Verrica Pharmaceuticals (VRCA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/12/vrca1600-300x169.png" alt="Shot of Sterile Pharmaceutical Manufacturing Laboratory where Scientists in Protective Coverall's Do Research, Quality Control and Work on the Discovery of new Medicine. VRCA stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p>Ending this list with another healthcare-related entity, <strong>Verrica Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrca-stock-quote/"><strong>VRCA</strong></a>) is a clinical-stage dermatology therapeutics firm. It develops medications for the treatment of skin diseases. Right now, it features a therapeutic called Ycanth (VP-102), which is in Phase 3 trials for the treatment of common warts. Given the sensitive needs to address such skin conditions, Verrica should be a top player.</p>



<p>Sure enough, VRCA stock has gained over 25% of market value since the start of the year. However, it&rsquo;s been a choppy ride. Those who got in during this year&rsquo;s highs are still underwater, implying lingering pessimism. This dynamic explains the <a href="https://fintel.io/ss/us/vrca">high short interest</a> of 26%. Not only that, VRCA&rsquo;s short interest ratio lands at 32.83 days to cover.</p>



<p>However, if shares start swinging higher for whatever reason, the bears would likely find themselves in trouble. It takes a while to unwind a short ratio of 33 days. Further, analysts anticipate massive growth in the coming years. Fiscal 2024 sales could hit $24.71 million, up 382.2%. And fiscal 2025 may see revenue up at $70.3 million. It&rsquo;s one of the short-squeeze stocks to keep on your radar.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/07/7-short-squeeze-stocks-that-could-beat-down-the-bears/">7 Short-Squeeze Stocks That Could Beat Down the Bears</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Short-Squeeze Stocks That Could Beat Down the Bears

Mondee Holdings (MOND – Research Report), the Consumer Cyclical sector company, was revisited by a Wall Street analyst today. Analyst Darren Aftahi...

Buy Rating Affirmed for Mondee Holdings Amid Debt Restructuring and Strategic Growth Initiatives

Mondee Holdings Non-GAAP EPS of -$0.17 misses by $0.11, revenue of $58.33M misses by $3.12M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Mondee Hldgs</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/mond-stock-quote/"><strong>MOND</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Mondee Hldgs reported earnings per share of -17 cents. This was below the analyst estimate for EPS of -15 cents.</li><li>The company reported revenue of $58.33 million.</li><li>This was 5.08% worse than the analyst estimate for revenue of $61.45 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/mond-stock-earnings-mondee-hldgs-for-q2-of-2024/">MOND Stock Earnings: Mondee Hldgs Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

MOND Stock Earnings: Mondee Hldgs Misses EPS, Misses Revenue for Q2 2024

Mondee Holdings, Inc. (MOND) Q2 2024 Earnings Call Transcript

Mondee Holdings (MOND) has issued an update. Mondee Holdings, Inc. has amended its financial agreements to extend the maturity of its loans and cre...

Mondee Holdings Revamps Financial Strategy Until 2028

In a report released today, Darren Aftahi from Roth MKM maintained a Buy rating on Mondee Holdings (MOND – Research Report), with a price target of...

Mondee Holdings' Strengthened Financial Position: A Buy Rating by Darren Aftahi

An announcement from Mondee Holdings ( ($MOND) ) is now available. Mondee Holdings, Inc. has successfully renegotiated the terms of its financing, ...

Mondee Holdings Bolsters Growth with Strategic Financial Restructuring

AIRS

MOND

NUVL

SCPH

TRUP

VRCA

WEST

ZYXI

Press Releases

Mondee to Participate in 26th Annual Needham Growth Conference

Mondee to Participate in Investor Conferences in March 2024

Mondee to Report Fourth Quarter and Full Year 2023 Financial Results on March 14, 2024

Mondee Reports Preliminary Unaudited Q4 & FY 2023 Results

Mondee to Report First Quarter 2024 Financial Results on May 10, 2024

Mondee Reports First Quarter 2024 Results

Mondee to Report Second Quarter 2024 Financial Results on August 8, 2024

Mondee to Hold Webcast on Second Quarter 2024 Financial Results and Anticipated New Financing on August 14, 2024

Mondee Reports Second Quarter 2024 Results and Announces Comprehensive Long-Term Refinancing of its Capital Structure

Mondee Finalizes Long-Term Extensions of Term Loan and Preferred Equity with Receipt of $15M Letter of Credit

Atour Lifestyle Holdings Limited - American Depositary Shares

Atour Lifestyle Holdings

Despegar.com

Global Business Travel Group, Inc. Class A Common Stock

Global Business Travel

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

Comments

Mondee Hldgs

Notizie

Ultime notizie per Mondee Hldgs (NASDAQ:MOND) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO